Nils Ekström1,2, Ann-Marie Svensson3, Mervete Miftaraj3, Stefan Franzén3, Björn Zethelius4,5, Björn Eliasson6, Soffia Gudbjörnsdottir6,3. 1. Department of Medicine, University of Gothenburg, Gothenburg, Sweden. nils.ekstrom@ki.se. 2. Department of Medicine Solna, Center for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden. nils.ekstrom@ki.se. 3. Center of Registers in Region Västra Götaland, Gothenburg, Sweden. 4. Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden. 5. Medical Products Agency, Uppsala, Sweden. 6. Department of Medicine, University of Gothenburg, Gothenburg, Sweden.
Abstract
AIM: To investigate the relative safety of various glucose-lowering agents as add-on medication to metformin in type 2 diabetes in an observational study linking five national health registers. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes who had been on metformin monotherapy and started another agent in addition to metformin were eligible for inclusion. The study period was 2005-2012. Adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of mortality, cardiovascular disease (CVD), coronary heart disease (CHD), stroke and congestive heart failure (CHF) were estimated using Cox proportional hazards models, weighted for a propensity score. RESULTS: Of the 20 422 patients included in the study, 43% started on second-line treatment with sulphonylurea (SU), 21% basal insulin, 12% thiazolidinedione (TZD), 11% meglitinide, 10% dipeptidyl peptidase-4 (DPP-4) inhibitor, 1% glucagon-like peptide-1 (GLP-1) receptor agonist and 1% acarbose. At the index date, the mean patient age was ~60 years for all groups except the GLP-1 receptor agonist (56.0 years) and SU (62.9 years) groups. Diabetes duration and glycated haemoglobin levels were similar in all groups. When compared with SU, basal insulin was associated with an 18% higher risk and TZD with a 24% lower risk of mortality [HR 1.18 (95% CI 1.03-1.36) and 0.76 (95% CI 0.62-0.94)], respectively. DPP-4 inhibitor treatment was associated with significantly lower risks of CVD, fatal CVD, CHD, fatal CHD and CHF. CONCLUSIONS: This nationwide observational study showed that second-line treatment with TZD and DPP-4 inhibitor as add-on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.
AIM: To investigate the relative safety of various glucose-lowering agents as add-on medication to metformin in type 2 diabetes in an observational study linking five national health registers. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes who had been on metformin monotherapy and started another agent in addition to metformin were eligible for inclusion. The study period was 2005-2012. Adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of mortality, cardiovascular disease (CVD), coronary heart disease (CHD), stroke and congestive heart failure (CHF) were estimated using Cox proportional hazards models, weighted for a propensity score. RESULTS: Of the 20 422 patients included in the study, 43% started on second-line treatment with sulphonylurea (SU), 21% basal insulin, 12% thiazolidinedione (TZD), 11% meglitinide, 10% dipeptidyl peptidase-4 (DPP-4) inhibitor, 1% glucagon-like peptide-1 (GLP-1) receptor agonist and 1% acarbose. At the index date, the mean patient age was ~60 years for all groups except the GLP-1 receptor agonist (56.0 years) and SU (62.9 years) groups. Diabetes duration and glycated haemoglobin levels were similar in all groups. When compared with SU, basal insulin was associated with an 18% higher risk and TZD with a 24% lower risk of mortality [HR 1.18 (95% CI 1.03-1.36) and 0.76 (95% CI 0.62-0.94)], respectively. DPP-4 inhibitor treatment was associated with significantly lower risks of CVD, fatal CVD, CHD, fatal CHD and CHF. CONCLUSIONS: This nationwide observational study showed that second-line treatment with TZD and DPP-4 inhibitor as add-on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.
Authors: Mark P Maskery; Christian Holscher; Stephanie P Jones; Christopher I Price; W David Strain; Caroline L Watkins; David J Werring; Hedley Ca Emsley Journal: J Cereb Blood Flow Metab Date: 2020-09-20 Impact factor: 6.200
Authors: Sofia Axia Karlsson; Christel Hero; Björn Eliasson; Stefan Franzén; Ann-Marie Svensson; Mervete Miftaraj; Soffia Gudbjörnsdottir; Katarina Eeg-Olofsson; Karolina Andersson Sundell Journal: Pharmacoepidemiol Drug Saf Date: 2017-08-11 Impact factor: 2.890
Authors: Thomas Nyström; Johan Bodegard; David Nathanson; Marcus Thuresson; Anna Norhammar; Jan W Eriksson Journal: Diabetes Obes Metab Date: 2017-03-16 Impact factor: 6.577
Authors: Frederik Persson; Thomas Nyström; Marit E Jørgensen; Bendix Carstensen; Hanne L Gulseth; Marcus Thuresson; Peter Fenici; David Nathanson; Jan W Eriksson; Anna Norhammar; Johan Bodegard; Kåre I Birkeland Journal: Diabetes Obes Metab Date: 2017-09-08 Impact factor: 6.577
Authors: Helen Strongman; Pasi Korhonen; Rachael Williams; Shahram Bahmanyar; Fabian Hoti; Solomon Christopher; Maila Majak; Leanne Kool-Houweling; Marie Linder; Paul Dolin; Edith M Heintjes Journal: BMJ Open Diabetes Res Care Date: 2017-05-29